Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation
June 02, 2022 16:01 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., June 02, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss...
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
May 13, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases...
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:00 ET
|
Cognition Therapeutics, Inc.
Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease Data Presented at Scientific Conferences Further Validate the Potential of σ-2 Modulators ...
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
May 04, 2022 17:54 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of...
Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
May 04, 2022 16:01 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases...
Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD
May 03, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the...
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
April 25, 2022 16:01 ET
|
Cognition Therapeutics, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
April 25, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
March 30, 2022 07:00 ET
|
Cognition Therapeutics, Inc.
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...